These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28221399)

  • 1. [Adverse reactions to anti-hormonal therapy affects adherence].
    von Wachenfeldt A; Andersson A; Fornander T; Isaksson Friman E; Johnsson A; Uddbom E; Uttermalm AC
    Lakartidningen; 2017 Feb; 114():. PubMed ID: 28221399
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of nonpharmacogenetic factors in endocrine therapy.
    McCowan C; Thompson AM
    Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer: Tamoxifen--when more might be better.
    Caldas C; Tannock IF
    Nat Rev Clin Oncol; 2013 Mar; 10(3):125-6. PubMed ID: 23380999
    [No Abstract]   [Full Text] [Related]  

  • 4. Adherence to long-term adjuvant hormonal therapy for breast cancer.
    Gotay C; Dunn J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemoprevention for breast cancer].
    Yamashiro H
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():88-91. PubMed ID: 23350371
    [No Abstract]   [Full Text] [Related]  

  • 6. Exemestane or tamoxifen?
    Ueda M; Toji E; Noda S
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tamoxifen and breast cancer: is everything known already?].
    Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
    Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
    [No Abstract]   [Full Text] [Related]  

  • 8. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
    Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
    Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].
    Jonat W
    MMW Fortschr Med; 2006 Mar; 148(12):10. PubMed ID: 16625996
    [No Abstract]   [Full Text] [Related]  

  • 10. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of endocrine treatments for breast cancer on health-related quality of life.
    Buijs C; de Vries EG; Mourits MJ; Willemse PH
    Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence rates and correlates in long-term hormonal therapy.
    Dunn J; Gotay C
    Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to K.I. Pritchard.
    Fontein DB; van de Velde CJ;
    J Clin Oncol; 2013 Dec; 31(35):4477-9. PubMed ID: 24190123
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant endocrine therapy for breast cancer.
    Rao RD; Cobleigh MA
    Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors and breast cancer prevention.
    Litton JK; Arun BK; Brown PH; Hortobagyi GN
    Expert Opin Pharmacother; 2012 Feb; 13(3):325-31. PubMed ID: 22242911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
    Mayer EL; Burstein HJ
    Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
    Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
    Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology.
    Morales L; Paridaens R; Timmerman D; Neven P
    Clin Cancer Res; 2006 Sep; 12(18):5603. PubMed ID: 17000698
    [No Abstract]   [Full Text] [Related]  

  • 20. Extended adjuvant therapy for breast cancer--how much is enough?
    Prowell TM; Stearns V
    J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.